Cancer is fundamentally a disease of gene regulation gone wrong. While much attention has focused on mutations in individual genes, researchers now understand that cancer also arises from widespread disruptions in how genes are physically organized and controlled inside the cell nucleus.
DNA inside the nucleus is not simply a flat string of letters - it folds into a complex three-dimensional architecture. Chromatin loops are structures where distant segments of DNA are brought into physical contact, allowing remote control elements called enhancers to activate or silence genes that may be millions of DNA base pairs away. These loops are essential for normal cell function and development.
In cancer, these looping patterns become abnormal. Genes that should be silent become activated, and multiple cancer-driving genes may be simultaneously switched on through shared loop networks. Researchers call the regions where many loops converge loop hubs - like bustling highway interchanges that coordinate traffic to many different destinations at once.
This study investigated how beta-catenin, a key protein in the WNT signaling pathway that is hyperactive in most colorectal cancers, creates aberrant loop hubs that drive cancer growth. Understanding this mechanism could reveal new therapeutic targets in CRC.
Beta-catenin, encoded by the CTNNB1 gene, is the central effector of the WNT signaling pathway - one of the most frequently mutated pathways in colorectal cancer. Under normal conditions, beta-catenin levels are tightly controlled and it remains outside the nucleus. When WNT signaling is abnormally activated (as occurs in roughly 90% of CRC cases), beta-catenin floods into the nucleus and activates hundreds of cancer-promoting genes.
Emerging evidence suggested that beta-catenin might do more than simply activate individual target genes - it might reorganize the entire three-dimensional architecture of the genome in cancer cells. The researchers hypothesized that beta-catenin physically clusters at specific genomic locations to create multi-gene loop hubs that drive coordinated cancer gene expression.
The team used HiChIP, a cutting-edge genomic technique that maps chromatin loops by detecting where specific proteins bridge distant DNA segments, to identify all beta-catenin-associated loops in colorectal cancer cells. This provided a genome-wide atlas of how beta-catenin reshapes the cancer genome's architecture.
By cross-referencing their findings with data from actual colorectal cancer tissue samples, they confirmed that the loop hub structures identified in laboratory cancer cell lines were also present in tumors from real patients - validating the clinical relevance of their laboratory discoveries.
Using HiChIP analysis, the researchers identified 78 distinct loop hubs in CRC cells. Each hub is defined as a genomic region where at least 10 genes are interconnected through a shared loop network - like a central hub that connects many spokes of a wheel.
These hubs were not random: genes within loop hubs showed significantly higher expression in cancer cells compared to both genes outside hubs and compared to the same genes in normal colon cells. The hubs appeared to create a cancer-specific environment of intense transcriptional activity.
When the researchers deleted beta-catenin from cancer cells, genes within loop hubs were disproportionately silenced. Conversely, when they activated the WNT pathway (which stabilizes beta-catenin), genes within loop hubs were preferentially switched on. This confirmed that beta-catenin specifically drives gene expression within these loop hub structures.
Analysis using an additional histone modification marker, H3K4me3 - a chemical tag on DNA packaging proteins that marks actively transcribed genes - confirmed the loop hubs are genuine centers of high transcriptional activity in cancer cells. The overlap between beta-catenin loops and H3K4me3 loops was dramatically higher within hub regions than elsewhere in the genome.
To test whether these loop hubs actually matter for cancer growth - rather than being merely an interesting structural observation - the team developed a creative experimental approach. They used a molecular tool called dCas9-KRAB-MeCP2 to artificially add DNA methylation specifically to the anchor points of the loops, without directly affecting the genes themselves.
DNA methylation is a chemical modification that attaches to DNA and blocks proteins from binding. By adding methylation specifically to the loop anchors, the researchers could disrupt the physical looping connections without directly targeting any specific gene. This allowed them to attribute any resulting changes to loop disruption rather than to other off-target effects.
The results were striking: disrupting loop hub structures significantly reduced the expression of genes within the hubs and, crucially, substantially inhibited the growth of cancer cells in culture. Cells with disrupted loop hubs proliferated more slowly and formed fewer colonies - key measures of cancer cell fitness.
These experiments established that the loop hubs are not passive structural features but are functionally essential for CRC cell growth. This makes them potential therapeutic targets: if a drug could disrupt loop hub assembly in cancer cells, it might suppress cancer growth.
The next question was: how does beta-catenin physically organize these loop hubs? The researchers discovered the answer involves a phenomenon called phase separation - the same biophysical process that causes oil to separate from water, but happening inside cells with proteins and nucleic acids instead of liquids.
When proteins undergo phase separation inside cells, they can spontaneously condense into dense, liquid-like droplets called condensates. These condensates concentrate specific molecules in one place, creating microenvironments with distinct chemical properties. Researchers have recently discovered that many key transcription factors form condensates at gene regulatory regions.
The researchers found that beta-catenin forms phase-separated condensates specifically in colorectal cancer cells and cancer tissue - these condensates were visibly present in CRC cells but were largely absent in normal colon cells. Using fluorescent tagging, they could directly observe beta-catenin condensates co-localizing with loop hub regions, confirming the physical connection.
The liquid-like properties of these condensates were confirmed using a technique called FRAP (Fluorescence Recovery After Photobleaching): when the researchers bleached the fluorescent signal within a condensate, the signal rapidly recovered as unbleached beta-catenin flowed back in - behavior characteristic of a fluid rather than a solid structure.
The researchers used a proximity-labeling technique called dCas9-APEX2 to identify exactly which proteins are present within beta-catenin condensates at loop hub sites. This approach uses a modified DNA-targeting tool to label all nearby proteins with biotin, which can then be captured and identified by mass spectrometry.
Among the proteins found within beta-catenin condensates, two emerged as particularly important: FUS and PARP1. These proteins play very different roles. FUS is an RNA-binding protein known for its strong phase-separation ability. PARP1 is an enzyme involved in DNA repair and chromatin modification that marks active genes with the H3K4me3 tag described earlier.
FUS acts as a scaffold: it has strong intrinsic phase-separation ability and forms droplets on its own. When mixed with beta-catenin in test tube experiments, FUS dramatically enhanced beta-catenin condensate formation at lower concentrations. Deleting FUS in cancer cells disrupted beta-catenin condensates and reduced loop strength within loop hubs.
PARP1 acts as a client: it cannot form condensates on its own but is recruited into beta-catenin condensates. Deleting PARP1 did not disrupt the physical structure of the condensates or the loops, but it did dramatically reduce H3K4me3 marks and gene expression at loop hub genes. Both proteins are needed for the full cancer-driving function of the hubs, but through completely different mechanisms.
This study presents a new mechanistic model for how colorectal cancer genes are coordinately activated. Rather than beta-catenin acting as a simple transcription factor that switches on individual genes one at a time, it forms phase-separated condensates that physically reorganize the genome into loop hubs where many cancer genes are simultaneously and strongly activated.
This coordinated regulation makes biological sense: cancer is unlikely to arise from abnormal expression of just one gene. Tumorigenesis requires the simultaneous dysregulation of many genes in coordinated networks. Loop hubs provide an elegant mechanism by which a single oncogenic factor (beta-catenin) can orchestrate the simultaneous activation of entire cancer gene programs.
An important nuance is that beta-catenin's phase separation in cancer appears to differ from its normal physiological behavior. Beta-catenin alone has limited intrinsic ability to form large condensates. The scaffold protein FUS is critical for enabling the larger, more stable condensates found specifically in cancer cells - suggesting that the FUS-beta-catenin interaction represents a cancer-specific vulnerability that normal cells do not have in the same form.
The discovery that both the physical architecture (FUS-dependent) and the epigenetic environment (PARP1-dependent) within condensates are essential for full cancer gene activation provides two distinct therapeutic angles: drugs could potentially target either the structural assembly of condensates or their internal chromatin-activating activity.
The findings establish that disrupting beta-catenin loop hubs suppresses colorectal cancer cell growth, validating these structures as genuine therapeutic targets. This opens several potential drug development directions, including targeting the phase separation behavior of beta-catenin itself or the FUS scaffold that enables its condensate formation in cancer cells.
PARP1 inhibitors are already an approved class of cancer drugs used in other cancer types. The discovery that PARP1 is a functional component of beta-catenin condensates at loop hubs in CRC provides a new rationale for investigating PARP1 inhibitors in colorectal cancer - a context where they have not traditionally been used.
More broadly, this research contributes to a growing understanding that the 3D organization of the cancer genome is a therapeutic target in its own right, not just a passive consequence of other cancer-driving events. Approaches that disrupt pathological chromatin architecture could complement existing targeted therapies.
Future studies will need to validate these findings in animal models and patient-derived cancer samples, and to determine whether disrupting loop hub assembly can overcome resistance to existing WNT pathway inhibitors - a major challenge in treating CRC that is driven by beta-catenin signaling.